Form 4 for KRYS Krystal Biotech, Inc.
Accepted 2026-06-26 18:45:51 ET · period of report 2026-06-25 · accession 0002114900-26-000009 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-06-26 18:45 | 2026-06-25 | KRYS | Thomas John Charles | EVP, GC | M - OptEx | $179.25 | +1,000 | 1,000 | New | +$179.2K |
| DT | 2026-06-26 18:45 | 2026-06-25 | KRYS | Thomas John Charles | EVP, GC | S - Sale+OE | $347.27 | -1,000 | 0 | -100% | -$347.3K |
| DT | 2026-06-26 18:45 | 2026-06-25 | KRYS | Thomas John Charles | EVP, GC | M - OptEx | $0.00 | -1,000 | 6,500 | -13% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-25 | M | A | 1,000 | $179.25 | 1,000 | D | — | — | (F1) The acquisition and sale of shares of the Company's common stock reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026. All transactions contemplated by the plan have been completed, and the plan has terminated in accordance with its terms. |
| 2 | Common | Common Stock | 2026-06-25 | S | D | 1,000 | $347.27 | 0 | D | — | — | (F1) The acquisition and sale of shares of the Company's common stock reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026. All transactions contemplated by the plan have been completed, and the plan has terminated in accordance with its terms. |
| 3 | Derivative | Stock Option (Right to Buy) | 2026-06-25 | M | D | 1,000 | $0.00 | 6,500 | D | $179.25 · — to 2035-02-27 | 1,000 Common Stock | (F2) The options vest ratably over a four-year period beginning on February 28, 2026. |